Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

This study is testing a targeted procedure called DEB-TACE (drug-eluting bead transarterial chemoembolization) as a local treatment for patients with large, hard-to-treat tumors from relapsed or treatment-resistant diffuse large B-cell lymphoma (a type of blood cancer). The technique delivers chemotherapy directly to the tumor through its blood supply. **You may be eligible if...** - You are 18–75 years old with confirmed diffuse large B-cell lymphoma - Your cancer has come back or stopped responding to multiple prior treatments - You have at least one bulky tumor (5 cm or larger, or confirmed bulky by imaging) - Your tumor has good blood supply visible on imaging - You previously responded to doxorubicin-based chemotherapy - You are in reasonably good health and have adequate blood counts and organ function **You may NOT be eligible if...** - Your tumor does not have sufficient blood supply for this procedure - Your blood counts or organ function are too low to tolerate treatment - You cannot tolerate the procedure for other medical reasons Talk to your doctor to see if this trial is right for you.